Synergistic Integration of Artificial Intelligence, Organoid Models, and Multi‐Omics Technologies in Contemporary Drug Discovery

Documenti analoghi

• Efficacy Evaluation of Adjuvant Therapeutic Drugs Against Early and Middle Stage Non‐Small Cell Lung Cancer Organoids
  di: Lin‐Jie Liu, et al.
  Pubblicazione: (2024)
• Discovery of Broad‐Spectrum Repurposed Drug Combinations Against Carbapenem‐Resistant Enterobacteriaceae (CRE) Through Artificial Intelligence (AI)‐Driven Platform
  di: Ming Li, et al.
  Pubblicazione: (2024)
• A Feasibility Test of the Disposable Drug Daughter Plate Combined with 384‐Pillar Plate for Patient‐Derived Organoid‐Based High Throughput Screening
  di: Kyunghyun Park, et al.
  Pubblicazione: (2024)
• Efficacy and Safety of Resveratrol in the Treatment of Bladder Cancer Derived Organoids
  di: Guang‐Yao Liu, et al.
  Pubblicazione: (2024)
• Quantitative Approaches to Accelerate MASH Drug Discovery and Development
  di: Yasmeen Abouelhassan, et al.
  Pubblicazione: (2025)